Beyang Therapeutics closes an oversubscribed Series A financing round, raising nearly $30 million to accelerate its AI-driven ExCEED platform's development. The round was co-led by Legend Capital and Shanghai Healthcare Capital.
Amount Raised
$30 Million
Round Type
Series A
ChengduBiotechnologyArtificial IntelligenceTherapeuticsInvestors
Description
Beyang Therapeutics Co., Ltd. has successfully closed an oversubscribed Series A financing round, raising nearly $30 million. The round was co-led by Legend Capital and Shanghai Healthcare Capital, with support from existing investors. The proceeds will be utilized to enhance the technological capabilities of the ExCEED platform and expand international R&D teams
Quick answer
Beyang Therapeutics Ltd raised $30 Million in a Series A round, dated August 12, 2026. Investors: China Medical System Holdings Limited, Fenglei Capital, Shanghai Sci Tech Innovation Center Capital, Harbor & Canton Capital, Yuanbio Venture Capital, Legend Capital, Shanghai Healthcare Capital and Root Venture Partners. Beyang Therapeutics Ltd is based in Chengdu, Sichuan, China.
- How much did Beyang Therapeutics Ltd raise?
- Beyang Therapeutics Ltd raised $30 Million in a Series A round on August 12, 2026.
- Who invested in Beyang Therapeutics Ltd?
- China Medical System Holdings Limited, Fenglei Capital, Shanghai Sci Tech Innovation Center Capital, Harbor & Canton Capital, Yuanbio Venture Capital, Legend Capital, Shanghai Healthcare Capital and Root Venture Partners are named as investors in this round.
- What does Beyang Therapeutics Ltd do?
- Beyang Therapeutics is an AI-driven innovative drug R&D company dedicated to building a 'DreamWorks' for innovative drug discovery.
- Where is Beyang Therapeutics Ltd based and how big is it?
- Beyang Therapeutics Ltd is based in Chengdu, Sichuan, China.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Beyang Therapeutics Ltd that raised within 45 days of this round, from Fundz verified event records.
- Big Picture Bio raised $2M (Pre-Seed) on September 18, 2026.
- Anew Labs raised $290M on September 16, 2026.
- Outer Bio raised $23M on August 26, 2026.
- Transcripta Bio raised $24M (Series A) on July 22, 2026.
- Integrated Biosciences raised $68M on July 21, 2026.
- Sightera Biosciences raised $3.4M (Pre-Seed) on July 17, 2026.
Who to call at Beyang Therapeutics Ltd, and when
A new round usually means Beyang Therapeutics Ltd is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Beyang Therapeutics Ltd raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Beyang Therapeutics Ltd, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Beyang Therapeutics Ltd. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Beyang Therapeutics Ltd raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansBeyang Therapeutics Ltd raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.